RECBIO-B(02179.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 211.82 million, loss narrowed by 37.82% YoY
NewTimeSpace News: August 19, 2026, RECBIO-B(02179.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 47 thousand, decreased by 99.57% YoY; Net Profit stood at loss of CNY 211.82 million, loss narrowed by 37.82% YoY; Profit Attributable to Shareholders stood at loss of CNY 211.82 million, loss narrowed by 37.82% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.34.
In terms of profitability, RECBIO-B Gross Profit changed from CNY 10.9 million in the same period last year to CNY 47 thousand in the current period, decreased by CNY 10.85 million; gross profit margin stayed unchanged from 100% in the same period last year to 100% in the current period, remained flat; net profit changed from loss of CNY 340.65 million in the same period last year to loss of CNY 211.82 million in the current period, increased by CNY 128.83 million; net profit margin changed from -3125.54% in the same period last year to -450682.98% in the current period, decreased by 447557.44 percentage points.
In terms of earnings quality, RECBIO-B Operating Profit changed from loss of CNY 326.77 million in the same period last year to loss of CNY 201.77 million in the current period, increased by CNY 125 million; Operating Profit Margin changed from -2998.14% in the same period last year to -429287.23% in the current period, decreased by 426289.1 percentage points.
In terms of financial soundness, RECBIO-B Debt-to-Asset Ratio changed from 88.49% in the same period last year to 68.8% in the current period, decreased by 19.69 percentage points; Total Equity changed from CNY 177.634 million in the same period last year to CNY 498.071 million in the current period, increased by CNY 320.44 million; Current Liabilities changed from CNY 881.45 million in the same period last year to CNY 766.93 million in the current period, decreased by CNY 114.52 million; Quick Ratio changed from 0.28 in the same period last year to 0.45 in the current period, increased by 0.17 percentage points.
In terms of R&D investment focus, RECBIO-B R&D Expenses changed from CNY 299.58 million in the same period last year to CNY 162.86 million in the current period, decreased by CNY 136.73 million; R&D to Total Revenue Ratio changed from 2748.71% in the same period last year to 346500% in the current period, increased by 343751.29 percentage points.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
